Dengue treatment in mild moderate and severe
Reading File
Finding Sources
Searching PubMed
"dengue" AND "treatment" AND "management"
Finding Sources
Searching the Web
dengue fever treatment mild moderate severe WHO guidelines 2024 2025
Reading File
Reading File
Reading Web Page
https://www.cdc.gov/dengue/hcp/clinical-care/index.html
Reading Web Page
https://www.cdc.gov/dengue/hcp/clinical-care/index.html
Reading File
I now have comprehensive information to provide a detailed answer. Let me compile everything.
Dengue Treatment: Mild, Moderate, and Severe
Dengue management is entirely supportive - there is no specific antiviral therapy. The WHO/CDC classification divides patients into Group A (mild/no warning signs), Group B (moderate/warning signs or co-morbidities), and Group C (severe dengue). Treatment decisions hinge on recognizing the triphasic course: febrile phase (days 1-3), critical/plasma-leakage phase (days 4-6, around defervescence), and recovery phase.
Warning Signs to Watch For
Before choosing a group, screen for these warning signs - their presence escalates management:
| Warning Sign |
|---|
| Severe abdominal pain or tenderness |
| Persistent vomiting (≥3 episodes/hr or ≥4/6 hrs) |
| Clinical fluid accumulation (pleural effusion, ascites) |
| Mucosal bleeding (gums, nose, vaginal, GI) |
| Altered mental status (irritability, drowsiness, GCS <15) |
| Liver enlargement ≥2 cm below costal margin |
| Progressive rise in hematocrit with rapid fall in platelets |
Group A - Dengue Without Warning Signs (Mild)
Setting: Outpatient / Home
Criteria: Hemodynamically stable, tolerating oral fluids, normal urine output, no warning signs, no significant co-morbidities.
Management:
- Bed rest
- Oral fluids - encourage abundant intake (water, ORS, coconut water, juices). This is the cornerstone.
- Antipyretics: Acetaminophen (paracetamol) only
- Avoid aspirin, salicylates, NSAIDs (e.g., ibuprofen) - they impair platelet function, increase bleeding risk, and risk Reye syndrome in children
- Avoid corticosteroids (not beneficial, potentially harmful)
- Tepid sponging for fever
- Daily CBC monitoring as clinically indicated
- Return precautions - educate patient and caregivers to return immediately if warning signs appear (critical phase is typically days 3-8 after fever onset)
- Patient should sleep under a mosquito net for ~3 weeks (viremic period) to prevent onward transmission
Group B - Dengue With Warning Signs or Co-existing Conditions (Moderate)
Setting: Inpatient
Group B1 - Co-existing conditions, no warning signs
Admit if patient has: pregnancy, acute renal failure, coagulopathy, diabetes, hypertension, asthma, chronic kidney/liver disease, obesity (BMI ≥30), age <1 yr or >65 yrs, lives alone or poor healthcare access, or receiving anticoagulants.
Management:
- Actively encourage and monitor oral fluid intake
- Acetaminophen for fever
- Monitor vital signs, urine output, warning signs, and compensated shock
- IV fluids if oral intake is inadequate or clinical status worsens
Group B2 - Warning Signs Present
Management:
- Baseline labs: CBC
- Monitoring: Vital signs, intake/output, urine output, hematocrit every 4-6 hours (more frequently if unstable)
- IV fluids: Start isotonic crystalloids (normal saline or Ringer's lactate)
- Titrate based on clinical condition and hematocrit trends
- Reduce gradually as patient stabilizes
- As capillary permeability normalizes (typically ~48 hrs after defervescence), progressively decrease IV fluid rates
- Careful monitoring to avoid both under-hydration AND fluid overload
- Do not give prophylactic platelet transfusions or routine corticosteroids
- Promptly identify signs of progression to severe dengue
Group C - Severe Dengue
Setting: Intensive Care
Defined by one or more of:
- Severe plasma leakage leading to shock or respiratory distress
- Severe bleeding (clinically significant)
- Severe organ involvement:
- Liver: AST or ALT >1000 U/L
- CNS: impaired consciousness
- Heart: myocarditis or arrhythmias
- Kidney: acute renal failure
Management:
1. Fluid Resuscitation (most critical intervention)
- Start IV bolus of isotonic crystalloids (normal saline or Ringer's lactate)
- Carefully titrate IV fluids using frequent hemodynamic and laboratory assessment
- Goal: balance resuscitation against fluid overload (a major cause of death)
- Reduce IV fluids gradually as patient stabilizes
- Monitor for shock from plasma leakage even without overt external bleeding
2. Bleeding Management
- Prophylactic platelet transfusions are NOT recommended (even at very low counts)
- Blood transfusion indicated only for:
- Clinically significant active bleeding with hemodynamic instability
- Hematocrit falling despite adequate fluid replacement (suggests occult bleeding)
3. Other Supportive Care
- Intensive hemodynamic monitoring
- Organ support as needed (renal replacement if AKI, mechanical ventilation if respiratory failure)
- Treat seizures if CNS involvement
- Early recognition and treatment of secondary bacterial infections
Key Drugs and Their Status
| Drug | Status |
|---|---|
| Acetaminophen (paracetamol) | USE - safe antipyretic and analgesic |
| NSAIDs (ibuprofen, diclofenac) | AVOID - impair platelet function, increase bleeding |
| Aspirin | AVOID - antiplatelet, risk of Reye syndrome in children |
| Corticosteroids | AVOID - no benefit, shown ineffective in dengue shock |
| Antibiotics | Only if secondary bacterial infection confirmed |
| Antivirals | None approved; treatment is entirely supportive |
Discharge Criteria (Group B/C)
Discharge is appropriate when:
- Afebrile for ≥24-48 hours without antipyretics
- Improving clinical status and appetite
- Adequate urine output
- No respiratory distress, stable hematocrit
- Platelet count trending upward
- No warning signs for at least 24-48 hours
Sources:
- Tintinalli's Emergency Medicine, Chapter 102 (Dengue Fever section)
- Red Book 2021: Report of the Committee on Infectious Diseases (Dengue, p. 522-523)
- Fitzpatrick's Dermatology (Dengue clinical management section)
- CDC Clinical Care of Dengue (updated April 2026)
- StatPearls - Dengue Fever (NCBI, 2025)
Note: WHO published new guidelines for clinical management of arboviral diseases including dengue in July 2025, and released pediatric dengue treatment guidance in October 2025. These represent the most current guidance. The core management remains supportive, but the new guidelines refine fluid management protocols and risk stratification for specific populations.
This is a shared conversation. Sign in to Orris to start your own chat.